Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type
The Journal of Pathology · 2023
DOI: 10.1002/path.6205 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, 2023. Verfasst von Thijmen Sijnesael und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Lobular, Carcinoma, Ductal, Breast. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Now, European Cooperation in Science and Technology, KWF Kankerbestrijding.
Abstract (Originalsprache)
Invasive lobular carcinoma (ILC) is a low‐ to intermediate‐grade histological breast cancer type caused by mutational inactivation of E‐cadherin function, resulting in the acquisition of anchorage independence (anoikis resistance). Most ILC cases express estrogen receptors, but options are limited in relapsed endocrine‐refractory disease as ILC tends to be less responsive to standard chemotherapy. Moreover, ILC can relapse after >15 years, an event that currently cannot be predicted. E‐cadherin inactivation leads to p120‐catenin‐dependent relief of the transcriptional repressor Kaiso (ZBTB33) and activation of canonical Kaiso target genes. Here, we examined whether an anchorage‐independent and ILC‐specific transcriptional program correlated with clinical parameters in breast cancer. Based on the presence of a canonical Kaiso‐binding consensus sequence (cKBS) in the promoters of genes that are upregulated under anchorage‐independent conditions, we defined an ILC‐specific anoikis resistance transcriptome (ART). Converting the ART genes into human orthologs and adding published Kaiso target genes resulted in the Kaiso‐specific ART (KART) 33‐gene signature, used subsequently to study correlations with histological and clinical variables in primary breast cancer. Using publicly available data for ER POS Her2 NEG breast cancer, we found that expression of KART was positively associated with the histological ILC breast cancer type ( p < 2.7E‐07). KART expression associated with younger patients in all invasive breast cancers and smaller tumors in invasive ductal carcinoma of no special type (IDC‐NST) (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Laboratory for Translational Breast Cancer Research, Katholieke Universiteit Leuven, Leuven, Belgium.
- Department of Biology, McMaster University, Hamilton, ON, Canada.
ORCID-Profile: Thijmen Sijnesael, François Richard, Max Ak Rätze, Thijs Koorman, Christine Desmedt, Patrick Wb Derksen
Förderung
- Breast Cancer Now
- European Cooperation in Science and Technology
- KWF Kankerbestrijding
- ZonMw
Zitieren
APA
Sijnesael, T., Richard, F., Rätze, M. A., Koorman, T., Bassey-Archibong, B., Rohof, C., Daniel, J., Desmedt, C., & Derksen, P. W. (2023). Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type. The Journal of Pathology. https://doi.org/10.1002/path.6205
Vancouver
Sijnesael T, Richard F, Rätze MA, Koorman T, Bassey-Archibong B, Rohof C, et al. Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type. The Journal of Pathology. 2023. doi:10.1002/path.6205
BibTeX
@article{Sijnesael2023,
author = {Sijnesael, Thijmen and Richard, François and Rätze, Max Ak and Koorman, Thijs and Bassey-Archibong, Blessing and Rohof, Christa and Daniel, Juliet and Desmedt, Christine and Derksen, Patrick Wb},
title = {Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type},
journal = {The Journal of Pathology},
year = {2023},
doi = {10.1002/path.6205}
}
EUVIMED